

Anderson Joseph  
Form 4  
December 22, 2011

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Anderson Joseph

(Last) (First) (Middle)

C/O AMARIN PHARMA,  
INC., 1430 ROUTE 206, SUITE 200

(Street)

BEDMINSTER, NJ 07921

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

AMARIN CORP PLC\UK [AMRN]

3. Date of Earliest Transaction  
(Month/Day/Year)

12/20/2011

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D) Code V Amount (D) Price			
Ordinary Shares <sup>(1)</sup>					11,683	D <sup>(2)</sup> <sup>(5)</sup>	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

## Edgar Filing: Anderson Joseph - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Pri Deriv Secur (Instr.	
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
						Code	V	(A)	(D)

Stock Option (right to buy)	\$ 1.03					(4)	02/10/2020	Ordinary Shares (1)	120,000
--------------------------------------	---------	--	--	--	--	-----	------------	------------------------	---------

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Anderson Joseph C/O AMARIN PHARMA, INC. 1430 ROUTE 206, SUITE 200 BEDMINSTER, NJ 07921	X			

## Signatures

/s/ Frederick Ahlholm, by power of attorney	12/22/2011
**Signature of Reporting Person	Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.  
As previously reported, Joseph Anderson (the "Reporting Person"), a partner of Abingworth LLP ("ALLP"), has been issued, to date, an aggregate of 11,683 ordinary shares, 50 pence par value per share ("Ordinary Shares"), of Amarin Corporation plc (the "Issuer"), in consideration of his services as a director of the Issuer. ALLP is the investment manager to a number of investment funds that include Abingworth Bioventures V L.P. ("ABV V") and Abingworth Bioventures V Co-Invest Growth Equity Fund LP ("AGE") (together, the "Abingworth Funds"). Under an agreement entered into between ALLP and the Reporting Person on December 20, 2011, the Reporting Person is deemed to hold all of these 11,683 Ordinary Shares (collectively, the "Abingworth Shares") on behalf of ALLP for the benefit of the Abingworth Funds (specifically, 5,842 Ordinary Shares are held for the benefit of ABV V and 5,841 Ordinary Shares are held for the benefit of AGE).
  - (3) As previously reported, the Reporting Person was granted an option on February 20, 2010, to purchase 120,000 Ordinary Shares under the Amarin Corporation plc 2002 Stock Option Plan in consideration of his services as a director of the Issuer. Under a prior agreement between the Reporting Person and ALLP, the Reporting Person was deemed to hold 103,200 of the 120,000 Ordinary Shares underlying the option for the benefit of ABV V and AGE (51,600 ordinary shares each). Pursuant to an agreement between the Reporting Person and ALLP entered into on December 20, 2011, the Reporting Person is now deemed to hold 96,000 of the 120,000 Ordinary Shares underlying the option (the "Abingworth Options") for the benefit of ABV V and AGE (48,000 Ordinary Shares each) and must exercise

## Edgar Filing: Anderson Joseph - Form 4

the Abingworth Options solely upon the direction of ALLP.

- (4) The stock option granted to the Reporting Person initially was scheduled to vest in four equal installments on each anniversary of the grant date (February 20, 2010). However, in light of the Issuer's announcement of favorable data relating to certain of its clinical trials, the Issuer's board of directors approved the acceleration of the vesting schedule relating to certain options (including the Reporting Person's options) granted by the Issuer, so that all of the vesting dates have been accelerated by a period of six months.

- (5) ALLP, on behalf of the Abingworth Funds, is entitled to direct the disposition of the Abingworth Shares and to receive any proceeds received in connection with the sale or disposition of the Abingworth Shares, and is entitled to the Ordinary Shares issuable upon exercise of the Abingworth Options. The Reporting Person's interest in the securities reported herein is limited to the extent of his pecuniary interest, if any, in the Abingworth Funds. This report shall not be deemed an admission that the Reporting Person, ALLP, each Abingworth Fund or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.